2-arylaminopyridine, pyrimidine or triazine derivative and preparation method and application thereof

A pyridine and pyrimidine technology, used in drug combinations, pharmaceutical formulations, active ingredients of heterocyclic compounds, etc., can solve problems such as inability to achieve patient drug concentration

Active Publication Date: 2016-11-16
WUXI SHUANGLIANG BIOTECH CO LTD
View PDF6 Cites 32 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nevertheless, the clinical experimental results of these irreversible inhibitors mentioned above show that these inhibitors still have certain limitations, such as toxic effects due to off-target effects, side effects caused by low selectivity, and inability to achieve sufficient drug concentrations in patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-arylaminopyridine, pyrimidine or triazine derivative and preparation method and application thereof
  • 2-arylaminopyridine, pyrimidine or triazine derivative and preparation method and application thereof
  • 2-arylaminopyridine, pyrimidine or triazine derivative and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0143] Embodiment 1: N-(5-((4-(benzo[d]isoxazol-3-yl)pyrimidin-2-yl)amino)-4-(difluoromethoxy)-2-(( 2-(Dimethylamino)ethyl)(methyl)amino)phenyl)acrylamide (Compound 14a)

[0144]

[0145] Compound 13a (40 mg, 0.14 mmol) was dissolved in dichloromethane (10 mL) and tert-butanol (1 mL), and 1-(3-dimethylaminopropyl)-3-ethylcarbadiene was added under ice-salt bath cooling Imine hydrochloride (EDCI, 35mg, 0.28mmol), triethylamine (19mg, 0.28mmol) and acrylic acid (13mg, 0.28mmol) were added, and the mixture was heated to room temperature for 2h. A saturated potassium carbonate solution was added to the reaction solution, stirred for 10 min, and separated, the organic phase was dried, evaporated to dryness, and purified by preparative chromatography to obtain 8 mg of a light yellow solid. 1 H NMR (400MHz, CDCl 3 ):δ10.23(s,1H),9.50(s,1H),8.69(d,J=5.0Hz,1H),8.57(d,J=8.0Hz,1H),7.68-7.57(m,4H) ,7.38-7.29(m,1H),6.85(s,1H),6.45-6.28(m,2H),5.71(m,1H),3.93(s,3H),2.96-2.88(m,2H),2.75...

Embodiment 2

[0155] Example 2: N-(5-((4-(benzo[d]isoxazol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiper (oxin-1-yl)phenyl)acrylamide (compound 14b)

[0156]

[0157] Compound 14b was prepared in the same manner as compound 14a, except that compound 13a was replaced with compound 13b. 1 HNMR (400MHz, CDCl 3 ):δ9.45(s,1H),8.68(d,J=5.0Hz,1H),8.56-8.54(m,2H),7.68-7.58(m,4H),7.39-7.35(m,1H), 6.85(s,1H),6.44-6.23(m,2H),5.78(d,J=9.1Hz,1H),3.93(s,3H),2.99-2.98(m,4H),2.69(m,4H) ,2.45(s,3H); MS(ESI)(m / z):[M+H] + 486.2.

[0158] 1-(4-bromo-5-methoxy-2-nitrophenyl)-N,N-dimethylpiperidin-4-amine (compound 11c)

[0159]

[0160] Compound 11c was prepared in the same manner as compound 11a except that N,N,N'-trimethylethylenediamine was replaced by N,N-dimethylpiperidin-4-amine. 1 H NMR (400MHz, CDCl 3 )δ8.22(s,1H),6.51(s,1H),3.97(s,3H),3.38(d,J=12.4Hz,2H),2.93-2.87(m,2H),2.45-2.31(m ,7H),1.95-1.92(m,2H),1.84-1.74(m,2H); MS(ESI)(m / z):[M+H] + 358.1.

[0161] 4-(Benzo[d]isoxazol-3-y...

Embodiment 3

[0167] Example 3: N-(5-((4-(benzo[d]isoxazol-3-yl)pyrimidin-2-yl)amino)-2-(4-(dimethylamino)piperidine-1 -yl)-4-methoxyphenyl)acrylamide (compound 14c)

[0168]

[0169] Compound 14c was prepared in the same manner as compound 14a, except that compound 13a was replaced by compound 13c. 1 HNMR (400MHz, CDCl 3 ):δ9.39(s,1H),8.65(d,J=5.0Hz,1H),8.52(d,J=7.9Hz,1H),8.41(s,1H),7.75-7.53(m,4H) ,7.36(t,J=7.4Hz,1H),6.76(s,1H),6.37-6.36(m,2H),5.78-5.77(m,1H),3.92(s,3H),3.18-3.15(m ,2H),2.81-2.76(m,3H),2.67(s,6H),2.25-2.22(m,2H),1.98-1.96(m,2H); MS(ESI)(m / z):[M +H] + 514.3.

[0170] (S)-1-(1-(4-bromo-5-methoxy-2-nitrophenyl)pyrrolidin-2-yl)-N,N-dimethylmethylamine (compound 11d)

[0171]

[0172] Except for replacing N,N,N'-trimethylethylenediamine with (S)-N,N-dimethyl-1-(pyrrolidin-2-yl)-methanamine, the same as compound 11a Preparation of compound 11d. 1 H NMR (400MHz, CDCl 3 ):δ8.12(s,1H),6.71(s,1H),3.95(s,3H),3.62-3.55(m,1H),2.72-2.61(m,2H),2.49-2.23(m,8H ),2.09-1.71(...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a 2-arylaminopyridine, pyrimidine or triazine derivative and a preparation method and application thereof. The 2-arylaminopyridines, pyrimidines or triazine derivatives may act on certain mutant forms of epidermal growth factor receptors such as L858R activating mutants, delE746_A750 mutants, Exonl9 deletion activating mutants and T790M drug resistant mutants , for use in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives are useful for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridines, pyrimidines or triazine derivatives, intermediates useful in the preparation of 2-arylaminopyridines, pyrimidines or triazine derivatives, and the use of 2-arylamino Pyridine, pyrimidine or triazine derivatives in the treatment of diseases mediated by various forms of EGFR.

Description

technical field [0001] The present invention belongs to the field of new medical technology, and particularly relates to 2-arylaminopyridine, pyrimidine or triazine derivatives or pharmaceutically acceptable salts or solvates thereof, which can be used for certain types of epidermal growth caused by certain variant forms Treatment or prevention of diseases or conditions mediated by factor receptors (eg L858R activating mutant, delE746_A750 mutant, Exonl9 deletion activating mutant and T790M drug resistant mutant). Such compounds or salts thereof, or solvates thereof, are useful in the treatment or prevention of many different cancers. The invention also relates to processes for the preparation of intermediates useful in the preparation of said compounds. Background technique [0002] The main treatments for cancer patients are radiotherapy, chemotherapy and surgery. Clinically, about 80% of lung cancers are non-small-cell lung cancer (NSCLC). According to statistics from t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D413/04C07D413/14C07D487/10C07D471/04C07D519/00C07D495/04C07D403/04C07D403/14C07D487/04A61K31/506A61K31/53A61K31/519A61K31/4439A61K31/444A61P35/00A61P35/02
CPCC07D403/04C07D403/14C07D413/04C07D413/14C07D471/04C07D487/04C07D487/10C07D495/04C07D519/00A61K31/403A61K31/437A61K31/506A61K31/519C07D401/04C07D405/04A61P35/00A61K31/44A61K31/505A61K31/53C07D213/73C07D239/42C07D251/42
Inventor 吴家权张海军曹焕岩金深霜张帅陆政华董健王赪晨谈秋
Owner WUXI SHUANGLIANG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap